Skip to content

Immunotherapy for asthma

Citation

  • Verified title: Immunotherapy for asthma
  • Publication year: 2025
  • DOI: 10.1038/s41423-025-01357-9
  • Metadata source: crossref-doi (confidence: high)
  • Original local title: Immunotherapy for asthma

Ingest Mode

  • Mode: focused manual crystallization mode
  • Meaning: this source page has been manually reviewed for the ILC2 regulatory-context question, including tissue compartment, model system, regulatory mediator, assay directness, and whether the source is primary or review-level evidence.
  • Required boundary: reusable claims should preserve species, tissue, mediator, disease model, and whether evidence is primary perturbation or review-level synthesis.

Source Type

  • review on asthma endotypes and immunotherapy
  • Evidence profile: asthma immunotherapy is increasingly organized around endotype-aware mechanisms, including type 2-high and type 2-low disease biology.
  • Knowledge note status: source-reviewed evidence note suitable for ILC2 regulation context.

Evidence Profile

  • Overall confidence: source-specific confidence is assigned to the biological claim below, not to PDF processing.
  • Evidence tags: #source/review #species/human #species/mouse #tissue/lung #cell/ILC2 #outcome/airway_hyperresponsiveness #outcome/inflammation #axis/asthma_endotype #axis/therapy #status/focused_crystallization
  • Primary biological axis: asthma immunotherapy is increasingly organized around endotype-aware mechanisms, including type 2-high and type 2-low disease biology.

Why It Matters Here

This source adds asthma immunotherapy review to the ILC2 regulatory map. Its durable use depends on tissue and source-type boundaries: primary studies can support source-specific mechanisms, while reviews should orient interpretation and point to primary anchors.

Key Findings

  • The review distinguishes type 2-high asthma from type 2-low asthma and frames therapy around endotype-specific immune mechanisms.
  • It is useful for translational orientation around biologics and immunotherapy logic.
  • It should not be treated as a primary ILC2 mechanism paper.
  • Use it to frame asthma therapy context while anchoring ILC-specific mechanisms to primary source notes.

Claim-Level Confidence

  • Medium confidence: useful review-level asthma immunotherapy and endotype framing.
  • Low confidence: individual ILC2 pathway claims require primary ILC-focused sources.

Methods and Context

  • Source-specific context: review-level synthesis of asthma immunology and immunotherapy literature.
  • Best wiki use: ILC2 functional regulation, tissue-context guardrails, and source routing.
  • Assay directness: strongest for the source tissue/model; indirect for lung disease unless lung data are present.

Caveats

  • Do not convert general asthma therapy discussion into ILC2-specific causal claims.
  • Preserve species, tissue compartment, mediator, and disease-model labels.
  • Reviews should frame the field; primary sources should anchor causal claims.

Contradiction and Supersession

  • Contradiction status: complements the current ILC2 regulatory map by adding tissue-context, developmental, metabolic, neuroimmune, epithelial, or therapeutic framing.
  • Supersession status: not superseded; use alongside direct pulmonary ILC2 sources with explicit evidence labels.

Pages Updated From This Source